• Disclosures of Relevant Financial Relationships
    It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.

    Faculty Relationship Identified With:
    Edgar Lerma, MD

    Consultant/Advisor: Vifor; Otsuka; Bayer

    Speaker’s Bureau: AstraZeneca; Bayer; Otsuka

     

    Planners and Peer Reviewers
    Timothy Hayes, MD, PhD; Charles V. Pollack Jr., MD; Kim Cheramie, MSN, RN-BC; Patrick Hayes and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.


    Accreditation Statement
    In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation Statements
    AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM.
    AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours.
    AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-24-017-H01-P.)
    Learners should only claim credit commensurate with the extent of their participation.


    This activity has been supported by an independent educational grant from Travere Therapeutics.

     

  • I am a:
  • If Physician, I am primarily a:
  • If Pharmacist, DOB:*
     - -
    2 digit month, 2 digit day, 4 digit year
  • I work primarily in:
  • I work primarily in the:
  • I engaged with this program via:
  • I would recommend this program and format to my colleagues.
  • I am aware of CE/CME courses available on Twitter from @ckd_ce.
  • 1. What is the most important aspect for a primary care provider to monitor in IgAN patients after referral to a nephrologist?*
  • 2. What is one key action a PCP can take to monitor disease progression in a patient with IgAN following nephrology referral?*

  • Attestation to Time Spent on Activity:
    AcademicCME designates this activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM, 0.50 CNE Contact Hours, or 0.50 CPE Contact Hours (0.05 CEUs) UAN # JA4008190-0000-24-017-H01-P for participation in the full educational activity.

  • I participated in this activity and claim:*
  • Date
     - -
    2 digit month, 2 digit day, 4 digit year
  • Should be Empty: